Tuesday, July 8, 2025

Trinity Biotech Announces Strategic Collaboration with Medical Artificial Intelligence Company PulseAI

Related stories

Conifers.ai Recognized in AI SOC Agents in Gartner Hype Cycle 2025

Conifers.ai, the agentic AI SOC platform transforming modern Security...

Groq Expands European Data Center Presence in Helsinki

Expands its unmatched global capacity for AI inference, in...

Capgemini to acquire WNS to lead in Agentic AI Operations

Creation of a leader in Intelligent Operations to capture...

Meet 11ai: The Voice-First AI Assistant That Does More Than Just Talk

As AI evolves quickly, one question remains: why do...
spot_imgspot_img

Trinity Biotech plc a commercial stage biotechnology company focused on human diagnostics and diabetes management solutions, including wearable biosensors, announced a strategic collaboration with medical artificial intelligence (“AI”) company PulseAI to enhance the Company’s recently acquired continuous glucose monitor (CGM) biosensor technology.

Under this collaboration, Trinity Biotech will provide a pool of unique multi-parameter CGM datasets from Trinity Biotech’s existing biosensor database to PulseAI. This data will be used to support the design and implementation of Trinity Biotech’s AI-driven health & wellness analytics platform. This platform will be a key component of Trinity Biotech’s CGM solution, further differentiating the affordable, needle-free and reusable diabetes management solution that Trinity plans to launch across global markets.

PulseAI are experts in evidence-based medical AI and have extensive experience in scaling AI algorithm training using medical sensor datasets. PulseAI have worked in association with Mayo Clinic to train their machine learning algorithms using large-scale datasets captured across millions of patients.

Also Read: EmpiRx Health Launches AI-Powered Technology Platform to Expand Clinically-Driven Pharmacy Care and Drive Innovative, Customer-First Solutions

Trinity Biotech Chief Technology Officer, Dr Gary Keating, stated, “This collaboration will deliver important insights as we develop our AI driven analytical platform. This project will harness the potential of using additional personalised data from in, on and around the body to enhance the utility of continuous glucose measurements, improving the user experience, increasing satisfaction, and providing superior metabolic insights.”

PulseAI Chief Executive Officer, Alan Kennedy, stated: “We’re delighted to partner with Trinity Biotech on this project which should result in the development of powerful data analytics, and lay the groundwork for future innovation and exploration in the context of glucose monitoring and broader health analytics.”

Source: GlobeNewsWire

Subscribe

- Never miss a story with notifications


    Latest stories

    spot_img